Furthermore, EpCAM-specific antibodies were conjugated with bouganin (citatuzumab bogatox) [120], Pseudomonas exotoxin A (oportuzumab monatox) [121] and alpha-amanitin [122], with interleukin-2 to activate T cells in the vicinity of EpCAM-positive tumor cells (huKS-IL2) [123], and with encapsulated inhibitory RNAs [124–126]. Here, EPCAM is linked to neoplasm.